HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinicopathological significance of MAML2 gene split in mucoepidermoid carcinoma.

Abstract
CRTC1-MAML2 and CRTC3-MAML2 fusions have been associated with favorable clinicopathological features of mucoepidermoid carcinomas. However, the significance of the MAML2 gene split has not been fully clarified. In the present study, 95 mucoepidermoid carcinomas (paraffin-embedded materials) were analyzed for CRTC1-MAML2 and CRTC3-MAML2 fusions by RT-PCR and for the MAML2 gene split by FISH. Quantitative RT-PCR for the CRTC1-MAML2 transcript was performed in selected cases. MLL gene involvement, which has been reported in some leukemia cases, was examined by FISH in fusion partner-unknown cases. CRTC1-MAML2 and CRTC3-MAML2 fusions were detected in 37 and 6 cases, respectively. The MAML2 gene split was detected in 62 cases, which included all CRTC1/3-MAML2 fusion-positive cases. The level of CRTC1-MAML2 transcript expression was highly variable, and its clinicopathological impact was unclear. The MLL gene split was not detected. Mucoepidermoid carcinomas negative for CRTC1/3-MAML2 and positive for the MAML2 gene split (n = 19) showed favorable clinicopathological tumor features similar to those positive for CRTC1/3-MAML2 fusions. Compared with negative cases (n = 33), mucoepidermoid carcinomas positive for the MAML2 split (n = 62) were associated with lower patient age, a mild female predilection, a smaller tumor size, less frequent nodal metastasis, a lower clinical stage, a lower histological grade, and longer overall and disease-free survival. The MAML2 gene split emerged as an independent prognostic factor for both overall and disease-free survival in multivariate prognostic analysis. The presence of the MAML2 gene split defines a distinct mucoepidermoid carcinoma subset that is associated clinicopathologically with favorable tumor features.
AuthorsHaruna Noda, Yoshihide Okumura, Takahisa Nakayama, Satoru Miyabe, Yukio Fujiyoshi, Hideo Hattori, Kazuo Shimozato, Hiroshi Inagaki
JournalCancer science (Cancer Sci) Vol. 104 Issue 1 Pg. 85-92 (Jan 2013) ISSN: 1349-7006 [Electronic] England
PMID23035786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2012 Japanese Cancer Association.
Chemical References
  • CRTC1 protein, human
  • CRTC3 protein, human
  • DNA-Binding Proteins
  • KMT2A protein, human
  • MAML2 protein, human
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • Trans-Activators
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Mucoepidermoid (genetics, pathology)
  • Child
  • DNA-Binding Proteins (genetics)
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Fusion
  • Histone-Lysine N-Methyltransferase
  • Humans
  • In Situ Hybridization, Fluorescence
  • Lymphatic Metastasis (genetics)
  • Male
  • Middle Aged
  • Myeloid-Lymphoid Leukemia Protein (genetics)
  • Nuclear Proteins (genetics)
  • Oncogene Proteins, Fusion (genetics)
  • Trans-Activators
  • Transcription Factors (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: